-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the huge market prospect of PD-1/PD-L1 is accelerating to attract various companies to rush to the beach
.
Among them, it is worth mentioning that, in addition to monotherapy, PD-1/PD-L1 monoclonal antibody is one of the important members of combination therapy
.
Therefore, clinical trials of many pharmaceutical companies are also continuously exploring the effect of PD-1/PD-L1 monoclonal antibody combined with other cancer therapies such as tumor immunotherapy, targeted therapy, radiotherapy or chemotherapy
.
According to the data, there are currently 5,683 clinical trials evaluating PD1/PDL1 mAbs as monotherapy or in combination with other therapies, of which 4,897 are active
.
Industry analysts believe that compared with 2017, the total number of clinical trials in the past five years has increased by 278%
.
In China, by the end of 2021, the number of PD-(L)1s has reached 12, including 6 domestic PD-1s, 2 imported PD-1s, 2 imported PD-L1s, and 2 domestic PD-L1s
.
In addition, there are a number of PD-(L)1s that are queuing up for approval, such as Henlius’ slulimumab, Jiahe Bio-B’s genusumab, and Lepu Bio’s pretlimumab etc.
_ It is worth noting that the industry believes that while more and more PD-(L)1 products are brought to the market to bring more new treatment options to the majority of patients, the competition in this track will become more intense, and product price reductions will enter the "normal" category.
"People's homes" will gradually begin to become a trend
.
It is understood that from January 1, 2022, the new version of the medical insurance catalog will be officially implemented, and the four domestic PD-1s are all included in the catalog
.
Among them, many products have been reduced in price
.
For example, sintilimab 10ml/100mg/bottle originally cost 2,843 yuan, and after entering the medical insurance, it was reduced to 1,080 yuan, a decrease of 62%; toripalimab 2ml: 80mg specification was reduced from 906.
08 yuan/vial to 825.
00 yuan/ Support, 6ml: 240mg specification dropped from 2100.
97 yuan/piece to 1912.
96 yuan/piece; BeiGene Tislelizumab 10ml: 100mg dropped from 2180 yuan/piece to 1450 yuan, a price reduction of 33%
.
Not only domestic varieties, but also imported varieties are affected by the impact of domestic varieties, and measures have been taken to reduce the burden on patients
.
For example, in the past, patients using K medicine cost nearly 300,000 yuan per year after charity assistance.
In 2021, the K medicine patient assistance project released a new plan: From January 1, 2021, patients only need to pay for 4 courses of treatment and cost 140,000 yuan
.
In this regard, the industry expects that more and more PD-1/L1 products will drop in price in the future when the PD-1/L1 track is crowded, which will undoubtedly be good news for the majority of patients
.
In fact, in the face of a market share of 10 billion yuan, it is not surprising that the number of clinical trials has soared and major pharmaceutical companies have entered the market
.
Just in the big environment, it should be noted that the entry threshold of PD-1/PD-L1 is not low, and the requirements for R&D strength are quite high, so R&D investment is not so easy for some enterprises
.
It is reported that Hengrui Medicine disclosed earlier that it has invested about 504 million yuan in research and development in the approved product project
.
In this context, the industry believes that pharmaceutical companies without technical support and innovation strength should still enter the market cautiously
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, it is worth mentioning that, in addition to monotherapy, PD-1/PD-L1 monoclonal antibody is one of the important members of combination therapy
.
Therefore, clinical trials of many pharmaceutical companies are also continuously exploring the effect of PD-1/PD-L1 monoclonal antibody combined with other cancer therapies such as tumor immunotherapy, targeted therapy, radiotherapy or chemotherapy
.
According to the data, there are currently 5,683 clinical trials evaluating PD1/PDL1 mAbs as monotherapy or in combination with other therapies, of which 4,897 are active
.
Industry analysts believe that compared with 2017, the total number of clinical trials in the past five years has increased by 278%
.
In China, by the end of 2021, the number of PD-(L)1s has reached 12, including 6 domestic PD-1s, 2 imported PD-1s, 2 imported PD-L1s, and 2 domestic PD-L1s
.
In addition, there are a number of PD-(L)1s that are queuing up for approval, such as Henlius’ slulimumab, Jiahe Bio-B’s genusumab, and Lepu Bio’s pretlimumab etc.
_ It is worth noting that the industry believes that while more and more PD-(L)1 products are brought to the market to bring more new treatment options to the majority of patients, the competition in this track will become more intense, and product price reductions will enter the "normal" category.
"People's homes" will gradually begin to become a trend
.
It is understood that from January 1, 2022, the new version of the medical insurance catalog will be officially implemented, and the four domestic PD-1s are all included in the catalog
.
Among them, many products have been reduced in price
.
For example, sintilimab 10ml/100mg/bottle originally cost 2,843 yuan, and after entering the medical insurance, it was reduced to 1,080 yuan, a decrease of 62%; toripalimab 2ml: 80mg specification was reduced from 906.
08 yuan/vial to 825.
00 yuan/ Support, 6ml: 240mg specification dropped from 2100.
97 yuan/piece to 1912.
96 yuan/piece; BeiGene Tislelizumab 10ml: 100mg dropped from 2180 yuan/piece to 1450 yuan, a price reduction of 33%
.
Not only domestic varieties, but also imported varieties are affected by the impact of domestic varieties, and measures have been taken to reduce the burden on patients
.
For example, in the past, patients using K medicine cost nearly 300,000 yuan per year after charity assistance.
In 2021, the K medicine patient assistance project released a new plan: From January 1, 2021, patients only need to pay for 4 courses of treatment and cost 140,000 yuan
.
In this regard, the industry expects that more and more PD-1/L1 products will drop in price in the future when the PD-1/L1 track is crowded, which will undoubtedly be good news for the majority of patients
.
In fact, in the face of a market share of 10 billion yuan, it is not surprising that the number of clinical trials has soared and major pharmaceutical companies have entered the market
.
Just in the big environment, it should be noted that the entry threshold of PD-1/PD-L1 is not low, and the requirements for R&D strength are quite high, so R&D investment is not so easy for some enterprises
.
It is reported that Hengrui Medicine disclosed earlier that it has invested about 504 million yuan in research and development in the approved product project
.
In this context, the industry believes that pharmaceutical companies without technical support and innovation strength should still enter the market cautiously
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
